Evidence map›Paper›PMID 41419646›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Cetuximab increases the risk of oral mucositis in radiotherapy-treated head and neck cancer compared to cisplatin: a systematic review of randomized controlled clinical trials.

Gabriella Alves Julião Costa, Reverton Soares Ribeiro, Clarice Lioba de Araújo, André Alves Crispim, Cassia Emanuella Nóbrega Malta, Edson Luiz Cetira Filho, Flávio da Silveira Bittencourt, Fabrício Bitu Sousa, Paulo Goberlânio de Barros Silva

Abstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gabriella Alves Julião CostaPostgraduate Program in Dentistry, UNICHRISTUS, João Adolfo Gurgel Street, 133, Cocó, Fortaleza, Ceará, ZC, 60190-180, Brazil. gabriellajuliao18@gmail.com.
Reverton Soares RibeiroGraduate in Dentistry, UNICHRISTUS, Fortaleza, Ceará, Brazil.
Clarice Lioba de AraújoPostgraduate Program in Oncology, Hospital Haroldo Juaçaba, Instituto Do Câncer Do Ceará, Fortaleza, Ceará, Brazil.
André Alves CrispimPostgraduate Program in Dentistry, UNICHRISTUS, João Adolfo Gurgel Street, 133, Cocó, Fortaleza, Ceará, ZC, 60190-180, Brazil.
Cassia Emanuella Nóbrega MaltaPostgraduate Program in Dentistry, UNICHRISTUS, João Adolfo Gurgel Street, 133, Cocó, Fortaleza, Ceará, ZC, 60190-180, Brazil.
Edson Luiz Cetira FilhoPostgraduate Program in Dentistry, UNICHRISTUS, João Adolfo Gurgel Street, 133, Cocó, Fortaleza, Ceará, ZC, 60190-180, Brazil.
Flávio da Silveira BittencourtPostgraduate Program in Oncology, Hospital Haroldo Juaçaba, Instituto Do Câncer Do Ceará, Fortaleza, Ceará, Brazil.
Fabrício Bitu SousaPostgraduate Program in Dentistry, UNICHRISTUS, João Adolfo Gurgel Street, 133, Cocó, Fortaleza, Ceará, ZC, 60190-180, Brazil.
Paulo Goberlânio de Barros SilvaPostgraduate Program in Dentistry, UNICHRISTUS, João Adolfo Gurgel Street, 133, Cocó, Fortaleza, Ceará, ZC, 60190-180, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the risk of oral mucositis in cetuximab-plus-radiotherapy compared to cisplatin-plus-radiotherapy in head and neck cancer patients. MATERIALS AND

methodsThis PROSPERO-registered systematic review conducted searches through PubMed, Scopus, Web of Science, LILACS, EBSCOhost, LIVIVO, Embase, and Grey literature (Google Scholar) until March 2025. Therefore, 10 articles were included for the evaluation in this systematic review and meta-analysis. Risk of bias (RoB) was assessed by Rob-2, and meta-analysis was performed (combined relative risk) in subgroups. The assessment of the certainty of evidence was analyzed by GRADE-pro.

resultsFrom 4118 reviewed articles, 10 RCTs were included in the systematic review and meta-analysis, and 4329 patients were evaluated. The Rob was predominantly low. The relative risk of oral mucositis was 1.15 (95% CI = 1.03 to 1.29) higher in cetuximab-plus-radiotherapy compared with cisplatin-plus-radiotherapy in head and neck cancer patients (p = 0.010). There was no heterogeneity (p = 0.890, I

conclusionCetuximab plus radiotherapy in head and neck cancer patients increases by 1.15 times the risk of oral mucositis. Clinical trials with preventing strategies for OM in cetuximab-treated patients were necessary.

Indexed as

Antineoplastic Agents, ImmunologicalCetuximabCisplatinHead and Neck NeoplasmsStomatitisChemoradiotherapyHumansRandomized Controlled Trials as TopicAntineoplastic Agents, ImmunologicalCetuximabCisplatinCarboplatinCetuximabCisplatinHead and neck neoplasmsOral mucositis

Identifiers

PMID41419646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.